Kurs & Likviditet
+2,32%
|
1,54 MNOK
Kursutveckling och likviditet under dagen för detta pressmeddelande
Kalender
2023-11-02 | Kvartalsrapport 2023-Q3 |
2023-08-17 | Kvartalsrapport 2023-Q2 |
2023-06-07 | Ordinarie utdelning AZT 0.00 NOK |
2023-06-06 | Årsstämma 2023 |
2023-05-04 | Kvartalsrapport 2023-Q1 |
2023-02-02 | Bokslutskommuniké 2022 |
2022-10-27 | Kvartalsrapport 2022-Q3 |
2022-08-18 | Kvartalsrapport 2022-Q2 |
2022-06-23 | Årsstämma 2022 |
2022-05-27 | Ordinarie utdelning AZT 0.00 NOK |
2022-04-28 | Kvartalsrapport 2022-Q1 |
2022-01-27 | Bokslutskommuniké 2021 |
2021-10-28 | Kvartalsrapport 2021-Q3 |
2021-08-19 | Kvartalsrapport 2021-Q2 |
2021-05-21 | Ordinarie utdelning AZT 0.00 NOK |
2021-05-20 | Årsstämma 2021 |
2021-04-22 | Kvartalsrapport 2021-Q1 |
2021-01-28 | Bokslutskommuniké 2020 |
2020-10-22 | Kvartalsrapport 2020-Q3 |
2020-08-19 | Kvartalsrapport 2020-Q2 |
2020-05-15 | Ordinarie utdelning AZT 0.00 NOK |
2020-05-14 | Årsstämma 2020 |
2020-04-23 | Kvartalsrapport 2020-Q1 |
2020-01-30 | Bokslutskommuniké 2019 |
2020-01-06 | Extra Bolagsstämma 2020 |
2019-10-24 | Kvartalsrapport 2019-Q3 |
2019-08-15 | Kvartalsrapport 2019-Q2 |
2019-05-16 | Ordinarie utdelning AZT 0.00 NOK |
2019-05-15 | Årsstämma 2019 |
2019-04-30 | Kvartalsrapport 2019-Q1 |
2019-01-30 | Bokslutskommuniké 2018 |
2018-10-18 | Kvartalsrapport 2018-Q3 |
2018-08-16 | Kvartalsrapport 2018-Q2 |
2018-05-09 | Ordinarie utdelning AZT 0.00 NOK |
2018-05-07 | Årsstämma 2018 |
2018-04-26 | Kvartalsrapport 2018-Q1 |
2018-02-01 | Bokslutskommuniké 2017 |
2017-10-19 | Kvartalsrapport 2017-Q3 |
2017-08-17 | Kvartalsrapport 2017-Q2 |
2017-05-12 | Ordinarie utdelning AZT 0.00 NOK |
2017-05-11 | Årsstämma 2017 |
2017-04-27 | Kvartalsrapport 2017-Q1 |
2017-02-02 | Bokslutskommuniké 2016 |
2016-10-26 | Kvartalsrapport 2016-Q3 |
2016-08-17 | Kvartalsrapport 2016-Q2 |
2016-05-12 | Ordinarie utdelning AZT 0.00 NOK |
2016-05-11 | Årsstämma 2016 |
2016-04-19 | Kvartalsrapport 2016-Q1 |
2016-02-11 | Bokslutskommuniké 2015 |
2016-02-11 | Kapitalmarknadsdag 2016 |
2015-11-03 | Kvartalsrapport 2015-Q3 |
2015-08-13 | Kvartalsrapport 2015-Q2 |
2015-05-13 | Ordinarie utdelning AZT 0.00 NOK |
2015-05-12 | Årsstämma 2015 |
2015-05-05 | Kvartalsrapport 2015-Q1 |
2015-02-17 | Bokslutskommuniké 2014 |
2014-11-05 | Kvartalsrapport 2014-Q3 |
2014-08-13 | Kvartalsrapport 2014-Q2 |
2014-05-15 | Ordinarie utdelning AZT 0.00 NOK |
2014-05-14 | Årsstämma 2014 |
2014-04-30 | Kvartalsrapport 2014-Q1 |
2014-02-14 | Bokslutskommuniké 2013 |
2013-11-01 | Kvartalsrapport 2013-Q3 |
2013-08-09 | Kvartalsrapport 2013-Q2 |
2013-06-13 | Kapitalmarknadsdag 2013 |
2013-05-28 | Ordinarie utdelning |
2013-05-27 | Årsstämma 2013 |
2013-05-07 | Kvartalsrapport 2013-Q1 |
2013-02-01 | Extra Bolagsstämma 2013 |
2013-01-07 | Bokslutskommuniké 2012 |
2012-11-06 | Kvartalsrapport 2012-Q3 |
2012-08-10 | Kvartalsrapport 2012-Q2 |
2012-05-07 | Ordinarie utdelning AZT 0.00 NOK |
2012-05-07 | Kvartalsrapport 2012-Q1 |
2012-05-07 | Årsstämma 2012 |
2012-02-21 | Bokslutskommuniké 2011 |
2011-11-08 | Kvartalsrapport 2011-Q3 |
2011-08-10 | Kvartalsrapport 2011-Q2 |
2011-05-13 | Kvartalsrapport 2011-Q1 |
2011-05-13 | Årsstämma 2011 |
2011-05-12 | Ordinarie utdelning |
2011-02-17 | Bokslutskommuniké 2010 |
2010-11-12 | Kvartalsrapport 2010-Q3 |
2010-08-10 | Kvartalsrapport 2010-Q2 |
2010-05-11 | Kvartalsrapport 2010-Q1 |
2010-05-04 | Årsstämma 2010 |
2010-03-03 | Bokslutskommuniké 2009 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2023-03-16 13:08:25
Tromsø, Norway, 16[th] of March 2023 - ArcticZymes Technologies ASA (OSE: AZT)
has filed a new patent application within the field of RNA based therapeutics.
The patent application covers a new nuclease enzyme composition and method-of
-use in the processing and analysis of RNA for therapeutic purposes. RNA therapy
is the treatment or prevention of diseases by using modified RNA molecules.
Developing RNA for therapeutic purposes is challenging and time consuming and
requires high-end instrumentation. The new enzyme can ease and improve the
analytical processes for therapeutic RNA for both developers and manufacturers.
There is currently no similar enzyme available on the market. ArcticZymes
Technologies has initiated client testing of a prototype, gathering performance
data and feedback prior to entering product development.
ArcticZymes Technologies ASA, CSO, Darren Ellis said: "We are excited by the new
patent application and prototype and how it can help clients accelerate their
processes. This again demonstrates the innovation capabilities at ArcticZymes
bringing forward patentable enzyme technology that can aid the development of
innovative therapies."
For more information, please contact:
ArcticZymes Technologies
CFO, Børge Sørvoll Tel: +47 95 29 01 87
CSO, Darren Ellis Tel: +47 47 31 50 97
ir@arcticzymes.com
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
The Company is listed on the Oslo Stock Exchange since 2005 as ArcticZymes
Technologies under the [AZT] ticker. Its headquarters are based in Tromsø,
Norway, at the SIVA Innovation Centre.
ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.
For more information, please visit the website: www.arcticzymes.com.